{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"condition":["Esophageal carcinoma","Carcinoma","Epithelial Tumors, Malignant","Non-small cell lung cancer","Colorectal cancer","Neoplasms, Glandular and Epithelial","Cervical cancer"],"disease":["Neoplasms, Glandular And Epithelial","Esophageal Carcinoma","Carcinoma","Cervical Cancer","Epithelial Tumors, Malignant","Non-small Cell Lung Cancer","Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/68117"],"location":["Australia"],"study_start_month":["8"],"keyword":["Urothelial cancer","Myeloid cells","Anti-TROP-2 chimeric antigen receptor","Pancreatic ductal adenocarcinoma","Gastric adenocarcinoma","Chimeric Antigen Receptor (CAR)","HR+/HER2- breast cancer","Triple-negative breast cancer","Monocytes","MT-302","TROP-2 expressing tumors","Ovarian epithelial","Lipid nanoparticle (LNP)","MRNA"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors","description":"MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.","dates":{"creation":"2023-08-15"},"accession":"68117","cross_references":{"ClinicalTrials___gov":["NCT05969041"]}}